CST3

Across TCGA pan-cancer cohorts, CST3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CST3 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CST3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CST3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LSCC show a favorable association.

LUAD, COAD, and UCEC are the cancer types where CST3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.766	1.000	.001	67	view →
COAD	DFS	Median	III,IV	0.835	1.000	.033	6	view →
UCEC	DFS	Tertile	All	0.937	0.773	.023	2	view →
LSCC	DFS	Median	All	0.875	0.720	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CST3–LUAD (OS)

Open the LUAD breakdown →